China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is booming as well as therapeutic areas where he sees promising science.
Providence spun off its venture capital arm and renamed it Allumia Ventures. The newly independent venture capital firm also recently closed its third fund, in which Providence invested $150 million. Allumia is looking to grow the fund by inviting 3-5 other health systems to be limited partner investors.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
AI startups should be thoughtful about which healthcare market(s) they’re going after, according to investors at Bessemer Venture Partners. Healthcare AI startups seeking venture capital face heightened expectations for scale, which requires access to substantial total addressable markets.
At a recent conference, Maria Berkman — who serves as head of medtech at Broadview Ventures and managing director at Longview Ventures — shared insights into the somewhat niche ecosystem of medtech investment.
Dan Easton, Unorthodox Ventures Principal, is one of the judges for the INVEST Pitch Perfect startup contest, which will focus on pediatric mental health. In response to emailed questions, Easton shared the firm's approach to healthcare startups.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Create Health Ventures announced the close of its inaugural $21 million fund, which is focused on technology for payers. This is because payers are “the lynchpin” for the types of change that the fund wants to see, such as better care access and improved population health outcomes, Managing Partner Amit Aysola said.
The boutique healthcare investment conference in Chicago is scheduled for May 21-22. Space is limited so register today!
Torl BioTherapeutics’ $158 million Series B-2 financing will finance clinical testing of its pipeline of antibody drug conjugates in development for various types of cancer. Neuroscience and immunology are among the therapeutic areas represented in our roundup of other recent biotech financings.
These health tech companies focused on the consumer and self-insured employer market will take part in the MedCity INVEST Pitch Perfect contest May 21-22 in Chicago. Register today!
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Seaport Therapeutics’ drug candidates are delivered through the lymphatic system, an approach that could overcome some limitations of neuropsychiatric medicines, including products from Sage Therapeutics. The startup stems from the research of PureTech Health.
The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago. In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities.
The conference will be held at the Ritz Carlton hotel in Chicago May 21-22. Space is limited., so secure your spot today to attend!
David Kereiakes, managing partner with Windham Venture Partners, shared his perspective of the health tech sector and investment trends he's seeing.
Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.